Europe does not lack health innovation.

It lacks the repeatable distribution channels required to turn promising companies into global category leaders.

That is the subject of this week’s HealthVC newsletter.

European healthtech companies often begin with real credibility. The science may be strong. The clinical relationships may be meaningful. The founder may understand the problem deeply. The company may have a respected hospital partner, a serious university connection, or early validation from patients and clinicians.

But credibility is not the same as commercial repeatability.

A company can build something valuable in one European country and still discover that the next country requires a different reimbursement pathway, a different procurement process, a different buyer map, a different language, a different clinical workflow, and a different market access strategy.

That fragmentation matters because venture outcomes depend on momentum.

A company does not become venture scale only because the product works. It becomes venture scale when the product can travel.

This week’s piece breaks down why Europe produces credible health companies but often struggles to scale them, why the first market is not just where you start but what you prove, why market size slides do not solve distribution risk, and why partnerships are only valuable when they unlock real market access.

Innovation starts the journey.

Distribution builds the outcome.